Specialty pharmacist integration into an outpatient neurology clinic improves pimavanserin access
Introduction: Access to pimavanserin, the only Parkinson disease-related psychosis treatment approved by the FDA, is restricted by insurance requirements, a limited distribution network, and high costs. Following initiation, patients require monitoring for safety and effectiveness. The primary objec...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Book |
| Published: |
American Association of Psychiatric Pharmacists,
2021-05-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|